Evidence map›Paper›PMID 29138154›Full record

SynthesisCanadian family physician Medecin de famille canadien2017

Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement.

Alex Mu, Erica Weinberg, Dwight E Moulin, Hance Clarke

Registry-linked trialAbstract readSystematic ReviewConsensus Statement
PubMed Full text at PMC
In one paragraph

Synthesis in Canadian family physician Medecin de famille canadien, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06030297 (Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.), which is not on this map. Cited by 59 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06030297 nacompletednot on this mapstarted 2023, after this paper: background citation

Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

TypeinterventionalSponsorUniversity of UtahRan2023 to 2026Enrolled75ConditionsPeripheral NeuropathyArmsDiode Laser fiber type Selective Stimulator, ZTlido 1.8 % Topical System, PeriCam PSI NR, Medoc Quantitative Sensory Testing, Inactive Topical System
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. ( +)-Catechin Alleviates CCI-Induced Neuropathic Pain by Modulating Microglia M1 and M2 Polarization via the TLR4/MyD88/NF-κB Signaling Pathway.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Research staff's experiences of how the COVID-19 pandemic impacted recruitment for a paediatric network study.International journal of qualitative studies on health and well-being · 2024
    Article
  17. Review
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Alex MuAnesthesiologist in the Pain Research Unit in the Department of Anesthesia at the Toronto General Hospital in Ontario. alexmu182@gmail.com.
Erica WeinbergGeneral practitioner practising in Toronto.
Dwight E MoulinProfessor in the Department of Clinical Neurological Sciences and the Department of Oncology at Western University in London, Ont.
Hance ClarkeAssistant Professor in the Department of Anesthesia and in the Transitional Pain Service of the Toronto General Hospital at the University of Toronto.
Toronto General Hospital · CARoyal College of General Practitioners · GBWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain. QUALITY OF EVIDENCE: A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement. MAIN MESSAGE: Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain. Tramadol and other opioids are recommended as second-line agents, while cannabinoids are newly recommended as third-line agents. Other anticonvulsants, methadone, tapentadol, topical lidocaine, and botulinum toxin are recommended as fourth-line agents.

conclusionMany pharmacologic analgesics exist for the treatment of neuropathic pain. Through evidence-based recommendations, the CPS revised consensus statement helps guide family physicians in the management of patients with neuropathic pain.

Indexed as

AnalgesicsCanadaChronic PainConsensusHumansNeuralgiaPain ManagementSocieties, MedicalAnalgesics

Identifiers

PMID29138154
PMCPMC5685445
OpenAlexW2978110657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.